Solid Biosciences Joins the Russell 3000® Index
Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, announced it has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective July 1st, 2024.
From Fighting Shoplifting to Pioneering Gene Therapies, the Startups in This Accelerator Are on the Front Lines of “Super Creativity”
The startups within UF Innovate, as well as the accelerator itself, are vivid examples of what creativity and innovation expert James Taylor, based in Scotland, describes as SuperCreativity—a phenomenon that many business leaders are trying to foster in today’s fast-changing business environment. It is a concept that goes beyond creativity or innovation alone.
AavantiBio Furthers Strategic Partnership With University of Florida To Research and Develop Next Generation Gene Therapy Capsids
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
AavantiBio and Aldevron Announce Strategic Partnership To Develop Next-Generation Gene Therapies for Rare Genetic Diseases
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem and who recently acquired UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices, announced a strategic collaboration to support the development and manufacturing of AavantiBio’s pipeline of therapies, including its lead program in Friedreich’s Ataxia (FA).
Here’s Why Sarepta Invested in a Departing Exec’s New Startup
One of Sarepta Therapeutics‘ longtime executives, Alexander “Bo” Cumbo, is leaving the company to launch a new gene therapy company — and his former employer is getting involved. Sarepta has invested $15 million in UF startup and UF Innovate | The Hub resident client AavantiBio, which launched Thursday with a total of $107 million. The […]
Gene Therapy Company AavantiBio Launches With $107 Million Series A Financing From Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, together with Sarepta Therapeutics, Inc., announced a $107 million Series A financing to create AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases. The private financing round includes a $15 […]
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia
The Muscular Dystrophy Association (MDA) and UF Innovate | The Hub resident client AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s Ataxia (FA), announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a gene-replacement therapy for the disease. MVP is MDA’s drug development […]